Skip to content

Evaluation of the Efficacy and Safety of a Hair Care Formulation for Enhancing Hair Growth

To evaluate the invivo efficacy and safety of hair care formulation in terms of hair growth ie improvement in AT ratio on healthy human subjects - Nil

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2025/01/078896
Enrollment
36
Registered
2025-01-17
Start date
Unknown
Completion date
Unknown
Last updated
2025-02-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Intervention1: Test Product A: Product to be applied on whole scalp and shaft, twice in a day for period of 28 days. Control Intervention1: Nil: NA

Sponsors

Eliea Wellness
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1)Healthy male & female subjects in the age group of 18 to 45 years. 2)Subject is having valid proof of identity and age. 3)Subjects suffering from Alopecia. 4)Subjects with hair thinning based on visual /dermatological assessment. 5)Subjects having hair density between 100-150 per square centimeter

Exclusion criteria

Exclusion criteria: 1)For Females: Being pregnant or breastfeeding or having stopped to breastfeed in the past three months. 2)Having refused to give his/her assent by not signing the consent form 3)Taking part in another study liable to interfere with this study 4)Having a chronic dermatosis liable to modify the cutaneous reactivity on the tested area 5)Being insulin-dependent diabetic or non insulin-dependent diabetic with a recent therapy (less than 6 months) 6)Having a progressive asthma (either under treatment or last fit in the last 2 years) 7)Being epileptic 8)Having non stabilized thyroid problems (requirement of a stabilized treatment for at least 6 months) 9)Having cutaneous hypersensitivity 10)Having a diagnosed or highly probable allergy to one or several compounds of the cosmetic products 11)Following a chronic or intermittent medicinal treatment comprising any of the following products: aspirin-based products, anti-inflammatories, antihistamines, anti-coagulants, corticotherapy, taken by general or local routes (the only medication permitted is paracetamol) 12)Having undergone a surgery requiring a general anaesthetic of more than one hour in the past 6 months.

Design outcomes

Primary

MeasureTime frame
Hair growth i.e. improvement in AT ratioTimepoint: Baseline, Day 7, Day 14 and Day 28

Secondary

MeasureTime frame
NilTimepoint: NA

Countries

India

Contacts

Public ContactDr Mohit Lalvani

MASCOT-SPINCONTROL India Pvt. Ltd.

poojayadav@mascotspincontrol.in02243349191

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026